Terlipressin的全球市场规模:各类型，各用途，各地区，范围及预测

Terlipressin市场规模及预测

2023 年Terlipressin市场规模为 39 亿美元，预计在 2024-2030 年预测期内将以 6.1% 的复合年增长率增长，到 2030 年将达到 51 亿美元。

伴随肾功能障碍（即肝肾症候群）的肝肾功能障碍发生率不断增加，正在推动Terlipressin市场的成长。Terlipressin全球市场报告提供了对市场的整体评估。它对关键细分市场、趋势、市场推动因素、阻碍因素、竞争格局以及在市场中发挥关键作用的因素进行了全面分析。

全球Terlipressin市场的定义

Terlipressin是一种血管活性药物，用于治疗低血压、肝肾症候群和出血性食道言语症。它与加压素类似，是赖氨酸加压素的激素原。已被选为肝肾综合征的治疗药物，主要用于此综合征。

Terlipressin全球市场概况

伴随肾功能障碍（即肝肾症候群）的肝肾功能障碍发生率不断增加，正在推动Terlipressin市场的成长。肝肾症候群的盛行率尚不清楚，但估计约 8-10% 的个体会发生肝肾症候群。Terlipressin比加压素具有更长的生物活性，副作用相对较少，并且能有效控制AVB。Terlipressin很少因失控出血而导致死亡，如果有的话，它是药物治疗的首选。使用Terlipressin作为药物是安全的，副作用很少见，通常在剂量减少后消失，并且已被证明可以改善肝肾综合征患者的预后。

它已在欧洲被批准用于肝肾综合征患者，并且正在美国进行试验以等待批准。研究表明，Terlipressin是治疗肝肾症候群患者研究最多的药物，与替代药物相比，Terlipressin更能改善患者的肾功能。可用性问题限制了Terlipressin市场的成长。Terlipressin目前在美国和加拿大尚未上市。不过，它在新西兰、澳大利亚、欧洲大部分地区、印度和阿拉伯联合大公国以及巴基斯坦可用。生长抑素、奥曲肽和伐普肽等替代药物的容易获得限制了市场的成长。

目录

第1章 全球Terlipressin市场:简介

• 市场概要
• 调查范围
• 前提条件

第2章 摘要整理

第3章 VERIFIED MARKET RESEARCH的调查手法

• 资料探勘
• 检验
• 第一手资料
• 资料来源一览

第4章 全球Terlipressin市场展望

• 概要
• 市场动态
  • 促进因素
  • 阻碍因素
  • 机会
• 波特的五力分析
• 价值链分析

第5章 Terlipressin的全球市场:各用途

• 概要
• 肝肾症候群(HRS)
• 腹水
• 败血性休克
• 其他

第6章 Terlipressin的全球市场:各类型

• 概要
• 98％以下
• 98％多

第7章 Terlipressin的全球市场:各地区

• 概要
• 北美
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 其他欧洲
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 全球其他地区
  • 南美
  • 中东·非洲

第8章 全球Terlipressin市场:竞争情形

• 概要
• 各公司的市场排行榜
• 主要的开发策略

第9章 企业简介

• EVER Pharma
• Hybio Pharmaceutical
• Sun Pharmaceutical Industries Ltd.
• Shanghai Soho-Yiming Pharmaceuticals
• Xi'an langene biological technology
• SGPharma
• Maya Biotech
• Hangzhou Huadi Group

第10章 附录

• 相关报告

Terlipressin Market Size And Forecast

Terlipressin Market size was valued at USD 3.9 Billion in 2023 and is projected to reach USD 5.1 Billion by 2030, growing at a CAGR of 6.1% during the forecast period 2024-2030.

The increasing occurrence of liver and kidney decreases with impaired kidney function that is hepatorenal syndrome is stimulating the growth of the Terlipressin Market. The Global Terlipressin Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Terlipressin Market Definition

Terlipressin is used as a vasoactive drug in the management of hypotension, hepatorenal syndrome, and for the treatment of bleeding oesophageal voice. It is similar to vasopressin, is a prohormone of lysine-vasopressin. It is the drug of choice for the treatment of hepatorenal syndrome and is mostly used for the same.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Terlipressin Market Overview

The increasing occurrence of liver and kidney decreases with impaired kidney function that is hepatorenal syndrome is stimulating the growth of the Terlipressin Market. The prevalence of hepatorenal syndrome is unidentified but is predicted to occur in approximately 8-10 percent of individuals. Terlipressin delivers longer biological activity and comparatively lesser side effects than vasopressin and is effective in controlling AVB. It reduces failure to control bleeding and mortality, is the first choice for pharmacological therapy when available. The use of terlipressin as a drug has been proved to be safe, with minimal side effects that usually disappear after dose reduction, and results in an improved outcome in patients with hepatorenal syndrome.

It is approved for use in Europe for patients with hepatorenal syndrome and trials to get it approved in the US are in progress. During findings, it has been found that terlipressin is studied the most for individuals with hepatorenal syndrome and results have shown improved renal function in affected individuals than alternatives. Availability issues are restraining the growth of the Terlipressin Market. At present, terlipressin is not available in the United States and Canada. But is available in New Zealand, Australia, much of Europe, India & UAE, and Pakistan. Easy availability of alternatives such as somatostatin, octreotide, and vapreotide restrains the growth of the market.

Global Terlipressin Market Segmentation Analysis

The Global Terlipressin Market is Segmented on the basis of Type, Application, And Geography.

Terlipressin Market, By Type

• >=98%
• <98%

Based on Type, the market is segmented into >=98% and <98%.

Terlipressin Market, By Application

• Hepatorenal Syndrome (HRS)
• Ascites
• Septic Shock
• Other

Based on Application, the market is segmented into Injection and Other.

Terlipressin Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World
• On the basis of Geography, the Global Terlipressin Market is classified into North America, Europe, Asia Pacific, and the Rest of the world.

Key Players

• The "Global Terlipressin Market" study report will provide a valuable insight with an emphasis on the global market including some of the major players such
• EVER Pharma, Hybio Pharmaceutical, Sun Pharmaceutical Industries Ltd., Shanghai Soho-Yiming Pharmaceuticals, Xi 'an langene biological technology, SGPharma, Maya Biotech, and Hangzhou Huadi Group
• . Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis.

TABLE OF CONTENTS

1. INTRODUCTION OF GLOBAL TERLIPRESSIN MARKET

• 1.1. Overview of the Market
• 1.2. Scope of Report
• 1.3. Assumptions

2. EXECUTIVE SUMMARY

3. RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1. Data Mining
• 3.2. Validation
• 3.3. Primary Interviews
• 3.4. List of Data Sources

4. GLOBAL TERLIPRESSIN MARKET OUTLOOK

• 4.1. Overview
• 4.2. Market Dynamics
  • 4.2.1. Drivers
  • 4.2.2. Restraints
  • 4.2.3. Opportunities
• 4.3. Porters Five Force Model
• 4.4. Value Chain Analysis

5. GLOBAL TERLIPRESSIN MARKET, BY APPLICATION

• 5.1. Overview
• 5.2. Hepatorenal Syndrome (HRS)
• 5.3.Ascites
• 5.4.Septic Shock
• 5.5. Other

6. GLOBAL TERLIPRESSIN MARKET, BY TYPE

• 6.1. Overview
• 6.2. >=98%
• 6.3. <98%

7. GLOBAL TERLIPRESSIN MARKET, BY GEOGRAPHY

• 7.1. Overview
• 7.2. North America
  • 7.2.1. U.S.
  • 7.2.2. Canada
  • 7.2.3. Mexico
• 7.3. Europe
  • 7.3.1. Germany
  • 7.3.2. U.K.
  • 7.3.3. France
  • 7.3.4. Rest of Europe
• 7.4. Asia Pacific
  • 7.4.1. China
  • 7.4.2. Japan
  • 7.4.3. India
  • 7.4.4. Rest of Asia Pacific
• 7.5. Rest of the World
  • 7.5.1. Latin America
  • 7.5.2. Middle East & Africa

8. GLOBAL TERLIPRESSIN MARKET COMPETITIVE LANDSCAPE

• 8.1. Overview
• 8.2. Company Market Ranking
• 8.3. Key Development Strategies

9. COMPANY PROFILES

• 9.1. EVER Pharma
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2. Hybio Pharmaceutical
  • 9.2.1. Overview
  • 9.2.2. Financial Performance
  • 9.2.3. Product Outlook
  • 9.2.4. Key Developments
• 9.3. Sun Pharmaceutical Industries Ltd.
  • 9.3.1. Overview
  • 9.3.2. Financial Performance
  • 9.3.3. Product Outlook
  • 9.3.4. Key Developments
• 9.4. Shanghai Soho-Yiming Pharmaceuticals
  • 9.4.1. Overview
  • 9.4.2. Financial Performance
  • 9.4.3. Product Outlook
  • 9.4.4. Key Developments
• 9.5. Xi 'an langene biological technology
  • 9.5.1. Overview
  • 9.5.2. Financial Performance
  • 9.5.3. Product Outlook
  • 9.5.4. Key Developments
• 9.6. SGPharma
  • 9.6.1. Overview
  • 9.6.2. Financial Performance
  • 9.6.3. Product Outlook
  • 9.6.4. Key Developments
• 9.7. Maya Biotech
  • 9.7.1. Overview
  • 9.7.2. Financial Performance
  • 9.7.3. Product Outlook
  • 9.7.4. Key Developments
• 9.8. Hangzhou Huadi Group
  • 9.8.1. Overview
  • 9.8.2. Financial Performance
  • 9.8.3. Product Outlook
  • 9.8.4. Key Developments

10. Appendix

• 10.1. Related Reports